Company profile: Azitra
1.1 - Company Overview
Company description
- Provider of microbiome-based dermatology therapeutics and consumer products, offering bioengineered live biotherapeutic candidates ATR-12 for Netherton syndrome, ATR-04 for EGFR inhibitor-associated rash, and protein candidate ATR-01 for ichthyosis vulgaris; and a microbiome dermatology platform to develop products for skin disease treatment and skin appearance improvement; plus topical ointments and creams for dryness, redness, flakiness, and inflammation.
Products and services
- Microbiome Dermatology Platform: A modular platform that leverages microbial and protein engineering to create microbiome-based products for skin disease treatment and skin appearance improvement.
- ATR-12: A custom-engineered live biotherapeutic product candidate engineered to secrete LEKTI for the treatment of Netherton syndrome.
- ATR-04: An auxotrophic live biotherapeutic product candidate using S. epidermidis to address EGFR inhibitor–associated rash.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Azitra
Biomodal
HQ: United Kingdom
Website
- Description: Provider of DNA sequencing tools and multiomic solutions enabling combined genetic and epigenetic analysis from low-input DNA, distinguishing 5mC and 5hmC via duet multiomics solution evoC and +modC, which integrates assay and software for use with existing NGS pipelines; and modality, an analysis package for efficient, scalable 5- and 6-base genome analysis to inform genome organization and gene regulation.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biomodal company profile →
Korro Bio
HQ: United States
Website
- Description: Provider of efficient, selective RNA editing solutions leveraging natural processes: OPERA, a platform using oligonucleotides for precise single-base edits to modulate protein function; KRRO-110, an oligonucleotide candidate for Alpha-1 Antitrypsin Deficiency via SERPINA1 RNA editing; and CHORDs, customized high-fidelity oligonucleotides for RNA deamination.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Korro Bio company profile →
Patch Biosciences
HQ: United States
Website
- Description: Provider of machine-designed DNA and an AI platform for sequence design to engineer more effective and durable gene therapies, leveraging large-scale DNA synthesis and machine learning. Offers synthetic promoter and untranslated region engineering, validated muscle promoters, and robust RNA UTRs for genetic and RNA-based medicines.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Patch Biosciences company profile →
Immuneering
HQ: United States
Website
- Description: Provider of bioinformatics-driven drug discovery developing investigational medicines, including IMM-1-104 targeting RAS-mutant advanced solid tumors with once-daily oral dosing, and IMM-6-415, a Deep Cyclic Inhibitor for RAF or RAS-mutant advanced solid tumors with twice-daily dosing; also maintains an Expanded Access Policy (not currently available).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immuneering company profile →
Bioline
HQ: United Kingdom
Website
- Description: Provider of fast, easy-to-use, guaranteed-to-work products developed by scientists to help customers focus on their scientific goals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bioline company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Azitra
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Azitra
2.2 - Growth funds investing in similar companies to Azitra
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Azitra
4.2 - Public trading comparable groups for Azitra
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →